This Biotech Stock Rocketed On Human Trials For New Cancer Drug

Cellectis (CLLS) popped early Wednesday after it and Dow's Pfizer (PFE) presented strong data for the first in-human trials of a cancer therapy at the American Society of Hematology conference.

X In morning trading on the stock market today, Cellectis launched 13.6%, near 27.30, after earlier rising as much as 18.5%, near a five-week high. Pfizer advanced 0.3%, near 36.70.

The Phase 1 studies tested a drug known as UCART19 in adult and pediatric patients with a form of acute lymphoblastic...

What feeling does this article give you?

#hashtags to follow:

CLLS [+]    Dow [+]    Pfizer [+]    PFE [+]    American Society of Hematology [+]    Phase 1 [+]   

More #news: